NEW YORK (GenomeWeb News) — Laboratory Corporation of America today said it plans to develop a gene-based companion diagnostic to be paired with a cardiac drug ARCA Discovery is currently developing, the companies said today.
The test will identify genetic variations of the alpha-2c and the beta-1 adrenergic receptors, which appear to affect the way heart failure patients respond to the ARCA drug bucindolol.